Llanda, Florida C.

HRN: 22-59-28  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/15/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
03/15/2023
03/22/2023
IV
600mg
Q6
Soft Tissue Mass Excision
Waiting Final Action 

Indication:  ProphylaxisEmpiric    Type of Infection:  Bone & JointSkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: